More on the Reta issue... · Peptide Resource Center

Kiki Riki

4d • General discussion

More on the Reta issue...

(Article by T Labs)

“RETA's days are numbered.”

“Here we go again.”

“FDA just did WHAT?”

“Another processor is gone.”

“Don't panic... but PAY ATTENTION.”

Every time I think we've reached peak insanity, this industry somehow finds another gear.

💳 Then THIS happened this week ...

I'm not going to name names, but one of the largest, and arguably the most recognizable, peptide brands in this industry lost access to one of its credit-card processors.

And no...

They're not even one of the companies named in the Lilly lawsuits.

These guys are MASSIVE.

Not some website that appeared six months ago.

Not some guy selling peptides on Facebook out of the trunk of the family SUV. 😂

We're talking about a major, established name that practically everybody who's been around this industry knows. If it can happen to them basically overnight, everybody in this industry should be paying attention.

NOW IT'S REALLY STARTING TO HIT HOME.

🔥 And then Lilly drops THIS.

Lilly filed six new federal lawsuits involving reta, including against Research Use Only peptide sellers.

But believe it or not, the six lawsuits aren't even what concerns me most.

➡ Lilly says it has now:

Referred 200+ individuals and companies to regulators and law enforcement

Reported 14,000+ websites, advertisements, social posts and product listings

Called on credit-card companies and payment processors to take action

Called on shipping and logistics companies to take action

Called on e-commerce platforms to take action

Called on social-media companies to take action

🚨 THIS IS THE PART EVERYBODY NEEDS TO UNDERSTAND.

➡ The six lawsuits are the part everybody sees. But they're only the visible tip of something much bigger.

➡ Lilly says it has reported 14,000+ websites, advertisements, social-media posts and product listings involving reta across more than 100 countries.

➡ At the same time, Lilly says it has referred 200+ individuals and entities to the FDA, Department of Justice, state attorneys general, law enforcement and professional licensing boards.

Now stop and think about those numbers.

🚨 SIX LAWSUITS.14,000+ LISTINGS.

Six lawsuits aren't going to eliminate 14,000 listings. That's clearly not the whole point.

What it looks like is that the lawsuits are the visible warning shot while pressure gets applied everywhere else. Because if the infrastructure starts disappearing, Lilly doesn't need to sue thousands of sellers individually.

(PRC already got hit with all of these! 😥

The new playbook:

A processor says no.

A bank says no.

A platform says no.

A carrier tightens its rules.

A logistics provider decides it's not worth the headache.

FIND IT → ORDER IT → PAY FOR IT → SHIP IT → ARRIVES AT YOUR DOOR

Break one or two links in that chain and access suddenly gets a whole lot harder. It's about how difficult it may become to find, purchase, pay for and physically receive research compounds at all.

📣 ACCESS IS GETTING HARDER.

Not necessarily tomorrow. Not necessarily everywhere at once. But the direction is becoming pretty damn difficult to ignore.

👀 And everybody is paying attention this time.

Normally regulatory news blows through this industry and half the peptide world barely notices. Not this time.

Social media is going crazy.

People I know who normally couldn't care less about FDA news are reaching out asking me:

“What the hell just happened?”

When THAT starts happening, I pay attention too.

Listen—here's what is really making this hit home.

At the end of the day, I've been hearing a lot of chatter from colleagues and competitors in this business. And several of them are basically saying:

➡ “You know what? Selling RETA just isn't worth the risk anymore.”

What I'm hearing is that some sellers intend to sell through whatever RETA inventory they have left—and then that's it.

No secret stash.

No special login access.

No hidden backroom inventory.

Just sell through the remaining stock, discontinue it and move on.

At least, that's how the recommendation from their attorneys has been relayed to me. When established sellers are being advised to walk away from RETA entirely, that should tell you how seriously people behind the scenes are taking this.

So... PANIC BUY?! 😂 NO!

PANIC BUYING IS STUPID. PLANNING AHEAD ISN'T.

I'm not going to insult your intelligence and pretend nothing is changing. Nobody knows exactly what research access looks like six months from now.

Nobody knows which payment options remain easy.

Nobody knows which processors change their policies next.

Nobody knows what Lilly, FDA, banks, platforms or logistics companies decide to do next.

And RETA is obviously sitting dead center in the spotlight. If RETA or other research compounds are already part of your upcoming research plans, don't wait until access gets harder to start thinking ahead.

Not emotionally. Not because Facebook announced the Peptide Apocalypse. Intelligently.

2 comments